The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Calcipotriol and Betamethasone cutaneous foam (Enstilar®) has been accepted as a topical treatment of psoriasis vulgaris in adults. It is noted that this product may be associated with a small budget impact.
Fosfomycin granules (Monuril®) have been accepted for:
- Treatment of acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females
- Prophylaxis in diagnostic and surgical transurethral procedures
It is noted that consideration should be given to national guidance on the appropriate use of antibacterial agents.
Liraglutide (Victoza®) has been rejected for use as monotherapy for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications. The manufacturer has not made a submission.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Retigabine to be discontinued||Drug Safety Update - September 2016 »|